Hepalys Pharma Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Seed

  • Latest Deal Amount
  • $1.85M

  • Investors
  • 6

Hepalys Pharma General Information

Description

Developer of therapeutic drugs designed for the treatment of non-alcoholic steatohepatitis. The company is developing a licensed drug candidate that has shown effectiveness in eliminating the condition and enhancing fibrosis, enabling patients to access a new treatment option for a critical medical condition.

Contact Information

Website
www.hepalys.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 3-11, Nihonbashi-honcho2-chome
  • Chuo-ku
  • Tokyo, Chuo-ku 103-0023
  • Japan
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Corporate Office
  • 3-11, Nihonbashi-honcho2-chome
  • Chuo-ku
  • Tokyo, Chuo-ku 103-0023
  • Japan

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Hepalys Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Seed Round 11-Oct-2023 $1.85M Completed Clinical Trials - Phase 2
1. Accelerator/Incubator Completed Startup
To view Hepalys Pharma’s complete valuation and funding history, request access »

Hepalys Pharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Class A Preferred
To view Hepalys Pharma’s complete cap table history, request access »

Hepalys Pharma Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Catalys Pacific Venture Capital Minority
DBJ Capital Corporate Venture Capital Minority
Medipal Innovation Corporate Venture Capital Minority
Mitsubishi UFJ Capital Venture Capital Minority
Nippon Venture Capital Corporate Venture Capital Minority
You’re viewing 5 of 6 investors. Get the full list »

Hepalys Pharma FAQs

  • When was Hepalys Pharma founded?

    Hepalys Pharma was founded in 2021.

  • Where is Hepalys Pharma headquartered?

    Hepalys Pharma is headquartered in Tokyo, Japan.

  • What industry is Hepalys Pharma in?

    Hepalys Pharma’s primary industry is Drug Discovery.

  • Is Hepalys Pharma a private or public company?

    Hepalys Pharma is a Private company.

  • What is the current valuation of Hepalys Pharma?

    The current valuation of Hepalys Pharma is .

  • What is Hepalys Pharma’s current revenue?

    The current revenue for Hepalys Pharma is .

  • How much funding has Hepalys Pharma raised over time?

    Hepalys Pharma has raised $1.85M.

  • Who are Hepalys Pharma’s investors?

    Catalys Pacific, DBJ Capital, Medipal Innovation, Mitsubishi UFJ Capital, and Nippon Venture Capital are 5 of 6 investors who have invested in Hepalys Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process